A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma

A phase 1 study was conducted to determine the dose-limiting toxicities and maximum tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD wa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Holkova, Beata, Yazbeck, Victor, Kmieciak, Maciej, Bose, Prithviraj, Ma, Shuo, Kimball, Amy, Tombes, Mary Beth, Shrader, Ellen, Wan, Wen, Weir-Wiggins, Caryn, Singh, Amanda, Hogan, Kevin T., Conine, Sarah, Sankala, Heidi, Roberts, John D., Shea, Thomas C., Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817887/
https://ncbi.nlm.nih.gov/pubmed/28103725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1276287
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados